Format

Send to

Choose Destination
Transl Res. 2012 Apr;159(4):313-25. doi: 10.1016/j.trsl.2012.01.001. Epub 2012 Feb 1.

Biomarkers in inflammatory bowel disease: current practices and recent advances.

Author information

1
Division of Gastroenterology, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA.

Abstract

Crohn's disease and ulcerative colitis represent the two main forms of the idiopathic chronic inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers provide reproducible, quantitative tools that can complement clinical assessment to aid clinicians in IBD diagnosis and management. C-reactive protein and fecal based leukocyte markers can help the clinician distinguish IBD from noninflammatory diarrhea and assess disease activity. The ability to differentiate between forms of IBD and predict risk for disease complications is specific to serologic tests including antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins. Advances in genomic, proteomic, and metabolomic array based technologies are facilitating the development of new biomarkers for IBD. The discovery of novel biomarkers, which can correlate with mucosal healing or predict long-term disease course has the potential to significantly improve patient care. This article reviews the uses and limitations of currently available biomarkers and highlights recent advances in IBD biomarker discovery.

PMID:
22424434
PMCID:
PMC3308116
DOI:
10.1016/j.trsl.2012.01.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center